GEO DataSet Links for PMC (Select 3914825) - GEO DataSets

Warning: The NCBI web site requires JavaScript to function. more...

Format

Summary
Summary (text)
Unique Identifier List

Sort by

Default order
Number of Samples (High to Low)
Number of Samples (Low to High)

Send to:

Choose Destination

File
Clipboard
Collections

Links from PMC

Items: 2

Select item 2000489061.

Neoadjuvant anastrozole alone or with gefitinib in early breast cancer

(Submitter supplied) Trial 223 was a placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. We used patients from arm B and C: anastrozole 1mg/d for the duration of the 16 week period plus placebo 1 tablet/d orally for 2 weeks. Patients in arm B were followed by gefitinib 250mg/d orally for 14 weeks whereas patients in arm C continued with placebo for 14 weeks.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
96 Samples

Download data: CEL

Series

Accession:: GSE48906

ID:: 200048906

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2000489052.

The NEWEST trial

(Submitter supplied) The NEWEST (Neoadjuvant Endocrine Therapy for Women with Estrogen-Sensitive Tumours) trial compared the clinical and biological activity of fulvestrant 500 mg vs 250 mg in the neoadjuvant setting. In this multi-centre phase II study, post-menopausal women with operable, locally advanced (T2, 3, 4b; N0-3; M0) ER-positive breast tumours were randomised to receive neoadjuvant treatment with either dose of fulvestrant for 16 weeks before surgery. more...